For research use only. Not for therapeutic Use.
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[1][2].
SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1].
SRX3207 has sufficient solubility in water (43 μmol/L)[1].
SRX3207 (10 mg/kg, orally) increases antitumor immune response[1].
| Catalog Number | I036642 |
| CAS Number | 2254693-15-5 |
| Synonyms | 3-[4-[[4-[4-(azetidin-1-ylmethyl)-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]phenyl]-5-morpholin-4-ylthieno[3,2-b]pyran-7-one |
| Molecular Formula | C29H29N7O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C29H29N7O3S/c1-19-21(16-34-9-2-10-34)17-36(33-19)25-7-8-30-29(32-25)31-22-5-3-20(4-6-22)23-18-40-28-24(37)15-26(39-27(23)28)35-11-13-38-14-12-35/h3-8,15,17-18H,2,9-14,16H2,1H3,(H,30,31,32) |
| InChIKey | ZZVOPDBZUNUMPR-UHFFFAOYSA-N |
| SMILES | CC1=NN(C=C1CN2CCC2)C3=NC(=NC=C3)NC4=CC=C(C=C4)C5=CSC6=C5OC(=CC6=O)N7CCOCC7 |
| Reference | [1]. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020. [2]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764. |
